We found that AZD2858 effectively downregulated the TGF-β signaling pathway by decreasing the expression of TGF-β receptor I, Smad2/3, and P107. The TGF-β signaling pathway plays a dual role in tumor suppression and tumor promotion. Here, RBL1 is linked to neoplasm.